Market Highlights
According to Market Research Future (MRFR) analysis, the Meningococcal Vaccines Market 2020 can thrive at a considerable CAGR across the analysis period 2019 to 2025. By 2025, the meningococcal vaccine market can touch USD Million from USD 172 Million in 2019.
Get Sample Report- https://www.marketresearchfuture.com/sample_request/8622
The rise in cases of meningococcal disease is expected to support the expansion of the market through the analysis period. As the mortality rate of meningococcal disease surge, the demand for vaccine increases. A high number of people have shown resistance to the disorder on vaccination. Thus, the increase in cases of prevention of meningococcal disorder by vaccination have created high demand. The rise in the production for meningococcal vaccine is observed to meet its rising need. These factors are expected to drive the market across the analysis period. In addition, hefty investment and increase in research and development for the identification and formulation of novel drug moiety to prevent meningococcal vaccine market can bolster the rise of the market through the review period. However, issues regarding approval of research projects can limit the growth of the meningococcal vaccine market in the years ahead.
Key Players
Baxter International, Novartis Pharmaceuticals Canada Inc, Pfizer Inc., Sanofi S.A., Biomed Pvt. Ltd., JN-International Medical Corporation, GlaxoSmithKline, and Serum Institute of India Ltd. among others are some influential meningococcal vaccines markets as listed by MRFR.
Market Segmentation
The segment assessment of the Meningococcal Vaccines global Market is done by treatment type and end-user.
- The treatment type based segments of the meningococcal market are polysaccharide, sub-capsular vaccine, and meningococcal conjugate vaccine. The polysaccharide segment can surge due to the increase in demand for products, such as MenACWY vaccines. In addition, the rise in demand for novel MenB vaccines can support the expansion of the meningococcal vaccine market across the analysis period.
- The end-user based segments of the meningococcal vaccines global market are research & academic institutes, and hospitals & clinics among others. The hospitals and clinics segment is expected to significantly control the meningococcal vaccines market in the years to come. The expansion of the hospitals and clinics segment can be attributed to the rise in the application of vaccines and easy accessibility to healthcare facilities. The rise in number of in-patients suffering from meningococcal disease can contribute to the expansion of the segment, which, in turn, impact the market rise. The increase in R&D for the investigation of new drug to treat meningococcal problem can cause the research laboratories and academic segment to surge in the years to come.
Regional Analysis
The application of meningococcal vaccines for the immunization of special risk groups, such as travellers and military personnel are highly recommended, although not-reimbursed. The launch of immunization program in meningitis prone countries include meningococcal vaccines only for risk groups. The increased in such cases and active steps taken by healthcare welfare controlling governments and organizations are forces that are likely to contribute to the expansion of the meningococcal vaccines market in the Asia Pacific region. The rise in interest for the introduction of multivalent and conjugate vaccine into scheduled national immunization programs in the MEA region can contribute to the regional market expansion. In North America, the easy availability of expertise can contribute to the expansion of the regional market. The ease of availability of C- and W-containing vaccines as issues related to these sero-groups are increasing can support the expansion of meningococcal market across the analysis period. Europe meningococcal vaccine market can surge due to the increase in cases of medical cases in the region.
Industry News
- November 2020
A renowned French pharma company, Sanofi, has received approval from the European Commission for its Meningococcal (MenACWY) vaccine MenQuadfi. The EC has given conformity for immunizing the individuals from the age of 12 months and older.
Browse Full Report-
https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622
Related Report-
Hearing Aids Market Research Report - Global Forecast till 2027
Patient Engagement Solutions Market Research Report - Global Forecast till 2027
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
